Alpha 2.0
Login Register
» Authors » C M Wendtner

C M Wendtner

Explore the profile of C M Wendtner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 44
Citations 1040
Followers 0
Related Specialties
Oncology
Hematology
General Medicine
Top 10 Co-Authors
M Hallek
B Emmerich
B Schmitt
M Volkenandt
M H Schmid-Wendtner
H Dohner
M Bergmann
K Fischer
S Stilgenbauer
J Bahlo
Published In
Leukemia
Dtsch Med Wochenschr
Internist (Berl)
Int J Hyperthermia
J Mol Recognit
Affiliations
Soon will be listed here.
Recent Articles
1.
Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
Al-Sawaf O, Robrecht S, Bahlo J, Fink A, Cramer P, V Tresckow J, et al.
Leukemia . 2020 Mar; 35(1):169-176. PMID: 32203141
Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The...
2.
Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia
Furstenau M, Bahlo J, Fink A, Lange E, Dreger P, Dreyling M, et al.
Leukemia . 2019 Oct; 34(3):924-928. PMID: 31611627
No abstract available.
3.
Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group
Hoechstetter M, Busch R, Eichhorst B, Buhler A, Winkler D, Eckart M, et al.
Leukemia . 2017 Aug; 31(12):2833-2837. PMID: 28804126
No abstract available.
4.
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group
Al-Sawaf O, Robrecht S, Bahlo J, Fink A, Cramer P, von Tresckow J, et al.
Leukemia . 2017 Jul; 31(10):2251-2253. PMID: 28745332
No abstract available.
5.
[Louse-borne-relapsing-fever in refugees from the Horn of Africa; a case series of 25 patients]
Seilmaier M, Guggemos W, Wieser A, Fingerle V, Balzer L, Fenzl T, et al.
Dtsch Med Wochenschr . 2016 Jul; 141(14):e133-42. PMID: 27404939
Background | Relapsing fever is divided into tick borne relapsing fever (TBRF) and louse borne relapsing fever (LBRF). This report describes 25 refugees from East Africa who were diagnosed to...
6.
Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia
Huelsemann M, Patz M, Beckmann L, Brinkmann K, Otto T, Fandrey J, et al.
Leukemia . 2014 Nov; 29(4):981-4. PMID: 25376373
No abstract available.
7.
[A rare cause of a progressive speech impairment]
Heckmann J, Ernst S, Kempf B, Hebecker R, Reithmeier T, Wendtner C
Med Klin Intensivmed Notfmed . 2013 Jul; 109(1):48-51. PMID: 23893010
No abstract available.
8.
[Severe oral mucositis in a patient with HIV infection]
Ehlert N, Seilmaier M, Guggemos W, Loscher T, Meurer A, Wendtner C
Dtsch Med Wochenschr . 2013 Jul; 138(31-32):1601-5. PMID: 23884748
History And Clinical Findings: A 50-year-old man with HIV infection (first diagnosed > 20 years ago) presented at our hospital with fulminant oral mucositis. Antiretroviral therapy (tenofovir, emtricitabine, raltegravir) had...
9.
Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells
Kruse U, Pallasch C, Bantscheff M, Eberhard D, Frenzel L, Ghidelli S, et al.
Leukemia . 2010 Oct; 25(1):89-100. PMID: 20944678
The pharmacological induction of apoptosis in neoplastic B cells presents a promising therapeutic avenue for the treatment of chronic lymphocytic leukemia (CLL). We profiled a panel of clinical multi-kinase inhibitors...
10.
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J, et al.
Lancet . 2010 Oct; 376(9747):1164-74. PMID: 20888994
Background: On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine...